{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:32:51Z","timestamp":1792607571952,"version":"4.5.0"},"reference-count":57,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The introduction of biological drugs in the management of chronic rhinosinusitis with nasal polyps (CRSwNP) is allowing new and increasingly promising therapeutic options. This manuscript aims to provide a multicenter trial in a real-life setting on Mepolizumab treatment for severe uncontrolled CRSwNP with or without comorbid asthma. Methods: A retrospective data analysis was jointly conducted at the Otolaryngology\u2013Head and Neck Surgery departments of La Sapienza University and San Camillo Forlanini Hospital in Rome. Both institutions participated by sharing clinical information on patients with CRSwNP treated with Mepolizumab. Patients were evaluated before starting Mepolizumab, at six months and at twelve months from the first drug administration. During follow\u2013up visits, patients underwent endoscopic evaluation, quality of life assessment, nasal symptoms assessment, and blood tests to monitor mainly neutrophils, basophils, eosinophils, and IgG, IgA, and IgE assay. Results: Twenty patients affected by CRSwNP and treated with Mepolizumab were enrolled (12 females and 8 males with a mean age of 63.7 years). Sixteen patients (80%) had concomitant asthma. During follow-up, a gradual improvement in nasal polyp score, quality of life and nasal symptoms, assessed by SNOT-22 and VAS and loss of smell measured by olfactory VAS, was found. Regarding blood tests, eosinophils decreased gradually, while other blood parameters showed no statistically significant changes. Conclusions: Mepolizumab has been shown to be effective in the therapeutic management of patients with CRSwNP. Further studies are needed to support our findings and better understand the underlying immune pathways to predict patients\u2019 response to biological treatment in CRSwNP.<\/jats:p>","DOI":"10.3390\/jcm13123575","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:21:28Z","timestamp":1718770888000},"page":"3575","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0378-8935","authenticated-orcid":false,"given":"Carlo","family":"Cavaliere","sequence":"first","affiliation":[{"name":"Department of Sense Organs, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7174-8126","authenticated-orcid":false,"given":"Antonella","family":"Loperfido","sequence":"additional","affiliation":[{"name":"Otolaryngology Unit, San Camillo Forlanini Hospital, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-459X","authenticated-orcid":false,"given":"Andrea","family":"Ciofalo","sequence":"additional","affiliation":[{"name":"Department of Sense Organs, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta","family":"Di Michele","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Interstitial Diseases, San Camillo Forlanini Hospital, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Begvarfaj","sequence":"additional","affiliation":[{"name":"Department of Sense Organs, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bellocchi","sequence":"additional","affiliation":[{"name":"Otolaryngology Unit, San Camillo Forlanini Hospital, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Bugani","sequence":"additional","affiliation":[{"name":"Department of Sense Organs, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"de Vincentiis","sequence":"additional","affiliation":[{"name":"Department of Sense Organs, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-9871","authenticated-orcid":false,"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[{"name":"Department of Sense Organs, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Millarelli","sequence":"additional","affiliation":[{"name":"Otolaryngology Unit, San Camillo Forlanini Hospital, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Plath","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sculco","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Masieri","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Sciences, Sapienza University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/11584340-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody","volume":"50","author":"Smith","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the Pathophysiology of Severe Asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front. Med."},{"key":"ref_4","unstructured":"(2024, March 01). 2023 GINA Report, Global Strategy for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2023\/07\/GINA-2023-Full-report-23_07_06-WMS.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/1744666X.2019.1656065","article-title":"The spectrum of therapeutic activity of mepolizumab","volume":"15","author":"Cavaliere","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Seccia, V., D\u2019Amato, M., Scioscia, G., Bagnasco, D., Di Marco, F., Fadda, G., Menzella, F., Pasquini, E., Pelaia, G., and Tremante, E. (2022). Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach. J. Pers. Med., 12.","DOI":"10.3390\/jpm12071096"},{"key":"ref_7","unstructured":"(2024, April 01). AIFA treatment plan for the prescription of Dupixent (Dupilumab), Xolair (Omalizumab) and Nucala (Mepolizumab) in the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Available online: https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2023-03-01&atto.codiceRedazionale=23A01126&elenco30giorni=false."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"789425","DOI":"10.3389\/falgy.2021.789425","article-title":"Corrigendum: Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA","volume":"2","author":"Claeys","year":"2021","journal-title":"Front. Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/alr.22487","article-title":"Revision surgery rates in chronic rhinosinusitis with nasal polyps: Meta-analysis of risk factors","volume":"10","author":"Loftus","year":"2020","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14639\/0392-100X-suppl.1-43-2023-01","article-title":"How to manage recurrences after surgery in CRSwNP patients in the biologic era: A narrative review","volume":"43","author":"Settimi","year":"2023","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_12","first-page":"287","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaci.2021.12.782","article-title":"Advances in chronic rhinosinusitis in 2020 and 2021","volume":"149","author":"Xu","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.14639\/0392-100X-N2422","article-title":"Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics","volume":"43","author":"Pipolo","year":"2023","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4027701","DOI":"10.1155\/2023\/4027701","article-title":"Dupilumab\u2019s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life","volume":"2023","author":"Loperfido","year":"2023","journal-title":"J. Immunol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12948-019-0106-2","article-title":"Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps","volume":"17","author":"Cavaliere","year":"2019","journal-title":"Clin. Mol. Allergy"},{"key":"ref_18","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"ref_19","unstructured":"Bellocchi, G., Loperfido, A., Passali, F.M., Millarelli, S., Velletrani, G., Perla, M., Di Michele, L., and Di Girolamo, S. (2023). Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience. Acta Biomed., 94."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13601-018-0219-6","article-title":"Visual analogue scale for sino-nasal symptoms severity correlates with sino-nasal outcome test 22: Paving the way for a simple outcome tool of CRS burden","volume":"8","author":"Doulaptsi","year":"2018","journal-title":"Clin. Transl. Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1007\/s00405-022-07339-1","article-title":"Correction to: Cross-cultural adaptation and validation of the SNOT-22 into Italian","volume":"279","author":"Mozzanica","year":"2022","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4193\/Rhino15.072","article-title":"Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments","volume":"54","author":"Toma","year":"2016","journal-title":"Rhinology"},{"key":"ref_23","first-page":"42","article-title":"Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities","volume":"151","author":"Alende","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic Rhinosinusitis with Nasal Polyps and Asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Meng, J., Zhou, P., Liu, Y., Liu, F., Yi, X., Liu, S., Holtappels, G., Bachert, C., and Zhang, N. (2013). The development of nasal polyp disease involves early nasal mucosal inflammation and remodelling. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082373"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","article-title":"Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era","volume":"10","author":"Mullol","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Loperfido, A., Cavaliere, C., Begvarfaj, E., Ciofalo, A., D\u2019Erme, G., De Vincentiis, M., Greco, A., Millarelli, S., Bellocchi, G., and Masieri, S. (2023). The Impact of Antibiotics and Steroids on the Nasal Microbiome in Patients with Chronic Rhinosinusitis: A Systematic Review According to PICO Criteria. J. Pers. Med., 13.","DOI":"10.3390\/jpm13111583"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic Rhinosinusitis with Nasal Polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: Targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/alr.22994","article-title":"The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2022","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nature12526","article-title":"Type 2 innate lymphoid cells control eosinophil homeostasis","volume":"502","author":"Nussbaum","year":"2013","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1398-9995.2008.01885.x","article-title":"Differential expression of the interleukin 5 receptor alpha isoforms in blood and tissue eosinophils of nasal polyp patients","volume":"64","author":"Gevaert","year":"2009","journal-title":"Allergy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.4049\/jimmunol.170.11.5359","article-title":"Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression","volume":"170","author":"Gregory","year":"2003","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/JAA.S270298","article-title":"Switch from IL-5 to IL-5-Receptor \u03b1 Antibody Treatment in Severe Eosinophilic Asthma","volume":"13","author":"Drick","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"212580","DOI":"10.7573\/dic.212580","article-title":"Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors?","volume":"8","author":"Menzella","year":"2019","journal-title":"Drugs Context"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/alr.23219","article-title":"Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up","volume":"14","author":"Desrosiers","year":"2024","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.anai.2021.01.010","article-title":"Nasal expression of the vascular endothelial growth factor and its receptors is reduced by mepolizumab in chronic rhinosinusitis with nasal polyposis","volume":"126","author":"Cavaliere","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_45","first-page":"37","article-title":"Nasal cytology","volume":"32","author":"Gelardi","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gallo, S., Castelnuovo, P., Spirito, L., Feduzi, M., Seccia, V., Visca, D., Spanevello, A., Statuti, E., Latorre, M., and Montuori, C. (2022). Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study. J. Pers. Med., 12.","DOI":"10.3390\/jpm12081304"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez-Sosa, M.S., Cabrera-Ram\u00edrez, M.S., Marrero-Ramos, M.D.C., D\u00e1vila-Quintana, D., Cabrera-L\u00f3pez, C., Carrillo-D\u00edaz, T., and Del Rosario, J.J.B. (2023). Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020485"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jaip.2020.01.009","article-title":"Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps","volume":"8","author":"Chan","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaci.2020.05.054","article-title":"Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis","volume":"146","author":"Lipworth","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"435","DOI":"10.14639\/0392-100X-N0716","article-title":"Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients","volume":"40","author":"Bandi","year":"2020","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_51","first-page":"320","article-title":"Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE","volume":"62","author":"Mullol","year":"2024","journal-title":"Rhinology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12016-022-08938-w","article-title":"Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps","volume":"64","author":"Tiotiu","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"17534666211009398","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: A 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Cavaliere, C., Masieri, S., Begvarfaj, E., Loperfido, A., Baroncelli, S., Cascone, F., and Ciofalo, A. (2024). Long-Term Perspectives on Chronic Rhinosinusitis with Nasal Polyps: Evaluating Recurrence Rates after Functional Endoscopic Sinus Surgery in the Biologics Era\u2014A 5-Year Follow-Up Study. J. Pers. Med., 14.","DOI":"10.3390\/jpm14030297"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12143","DOI":"10.1002\/clt2.12143","article-title":"Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE)","volume":"12","author":"Contoli","year":"2022","journal-title":"Clin. Transl. Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3906\/sag-1912-62","article-title":"Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: Single center, real life study","volume":"50","author":"Yilmaz","year":"2020","journal-title":"Turk. J. Med. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/12\/3575\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:00:41Z","timestamp":1760108441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/12\/3575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["jcm13123575"],"URL":"https:\/\/doi.org\/10.3390\/jcm13123575","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}